NVCR NovoCure Ltd

Price (delayed)

$11.755

Market cap

$1.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.95

Enterprise value

$1.61B

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating ...

Highlights
The net income has plunged by 124% YoY and by 5% from the previous quarter
NVCR's EPS has dropped by 122% year-on-year and by 5% since the previous quarter

Key stats

What are the main financial stats of NVCR
Market
Shares outstanding
107.09M
Market cap
$1.26B
Enterprise value
$1.61B
Valuations
Price to book (P/B)
3.47
Price to sales (P/S)
2.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.17
Earnings
Revenue
$509.34M
EBIT
-$232.87M
EBITDA
-$221.9M
Free cash flow
-$100.43M
Per share
EPS
-$1.95
Free cash flow per share
-$0.94
Book value per share
$3.39
Revenue per share
$4.79
TBVPS
$10.77
Balance sheet
Total assets
$1.15B
Total liabilities
$783.63M
Debt
$596.24M
Equity
$362.5M
Working capital
$855.29M
Liquidity
Debt to equity
1.64
Current ratio
5.78
Quick ratio
5.56
Net debt/EBITDA
-1.59
Margins
EBITDA margin
-43.6%
Gross margin
74.8%
Net margin
-40.6%
Operating margin
-45.7%
Efficiency
Return on assets
-17.9%
Return on equity
-51.6%
Return on invested capital
-16.6%
Return on capital employed
-24.1%
Return on sales
-45.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
-2.77%
1 week
-7.59%
1 month
-11.01%
1 year
-81.28%
YTD
-21.27%
QTD
-24.79%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$509.34M
Gross profit
$381.06M
Operating income
-$232.87M
Net income
-$207.04M
Gross margin
74.8%
Net margin
-40.6%
NovoCure's operating margin has shrunk by 175% YoY and by 2.7% QoQ
NovoCure's operating income has shrunk by 160% YoY and by 3.9% QoQ
NovoCure's net margin has plunged by 136% YoY and by 3.8% from the previous quarter
The net income has plunged by 124% YoY and by 5% from the previous quarter

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
N/A
P/B
3.47
P/S
2.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.17
NVCR's EPS has dropped by 122% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 86% lower than the 5-year quarterly average of 25.6 and 58% lower than the last 4 quarters average of 8.5
The equity has declined by 18% year-on-year and by 8% since the previous quarter
NVCR's price to sales (P/S) is 86% lower than its 5-year quarterly average of 18.4 and 63% lower than its last 4 quarters average of 6.8
The company's revenue fell by 5% YoY

Efficiency

How efficient is NovoCure business performance
NVCR's return on sales has dropped by 175% year-on-year and by 2.7% since the previous quarter
NovoCure's ROIC has plunged by 155% YoY and by 7% from the previous quarter
NovoCure's return on equity has shrunk by 146% YoY and by 10% QoQ
The company's return on assets has shrunk by 127% YoY and by 6% QoQ

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 46% more than its total liabilities
The company's quick ratio fell by 18% YoY and by 14% QoQ
The company's current ratio fell by 17% YoY and by 13% QoQ
NovoCure's debt is 64% more than its equity
NVCR's debt to equity is up by 24% YoY and by 9% QoQ
The equity has declined by 18% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.